Table 1.

Previously reported cases of essential thrombocythemia (ET) with transformation to chronic myelogenous leukemia (CML) with the emergence of the Philadelphia chromosome.

No.	Age/Sex	CMPD	JAK2 V617F	Chromosomal translocation	Initial treatment for the CMPD	Transformation to CML (duration in years)	Chromosomal translocation	CML treatment	Response for CML treatment	Outcome	Ref.
1	58/F	ET	ND	Negative	HU	18	Positive	Interferon alpha, UR-PBSCT	CCyR	Improve	[20]
2	65/F	ET	ND	Negative	HU	6	Positive	Imatinib mesylate	PCyR	Improve	[17]
3	73/M	ET	ND	Negative	HU	12	Positive	Imatinib mesylate	PCyR	Progress	[18]
4	38/F	ET	ND	Negative Monosomy 6,22	Aspirin	13	Positive + monosom7	Imatinib mesylate + RIST	CCyR	Improve	[19]
5	82/M	ET	ND	Negative	HU	9	Positive double Ph1	Imatinib mesylate Nilotinib	CCyR	Progress	[21]
6	49/F	ET	ND	Negative	Aspirin	7	Positive	HU + Nilotinib, after three months, Nilotinib replaced with IM	CCyR	Improve	Current case

F – Female; M – Male; ET – essential thrombocythemia; HU – hydroxyurea; ND – not detected; IM – imatinib mesylate; CCyR – complete cytogenetic remission; RIST – reduced intensity allogeneic stem cell transplant; UR-PBSCT – unrelated donor peripheral blood stem cell transplantation; CML – chronic myelogenous leukemia. The first reported case [17] was treated initially with HU. Anagrelide was then used to treat the increasing platelet counts, while the CML was managed with imatinib. Almost all reported cases [18–21] have been treated with HU and imatinib. The time between initial diagnosis of ET and transformation to CML was six, 12, 13, nine, and 18 years, respectively. Our case had a history that covered a period of seven years.